Mr. Craig R Villari, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 510 8th Ave Ne Ste 310, Issaquah, WA 98029 Phone: 425-454-3938 Fax: 425-392-3561 |
News Archive
The National Radiation Oncology Registry (NROR) pilot program will serve as the basis for the creation of a nationwide electronic registry to capture reliable, population-based information on radiation treatment delivery and health outcomes and will be supported by an innovative information technology (IT) infrastructure that will maximize efficiency through the automated collection and electronic transfer of data, according to research presented at the American Society for Clinical Oncology (ASCO) Quality Care Symposium.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Patients and researchers will be able to look at data on the safety of different medicines announced Health Minister, Lord Warner today. The move is part of a series of measures to further improve the drug side effect reporting system - the Yellow Card Scheme, which is used by the medicines watchdog (MHRA) to monitor the safety of medicines in the UK.
Industry leader in family-based treatment for almost twenty years, New Haven Residential Treatment Center announced the opening of its new residential home and new school for teen girls on its Saratoga Springs Campus, located 30 minutes south of Salt Lake City.
› Verified 4 days ago